Does orencia increase the risk of skin cancer?

Does Orencia raise skin cancer risk?

Orencia (abatacept) is a biologic used to treat rheumatoid arthritis and other autoimmune conditions. It works by suppressing parts of the immune system. This can make people more susceptible to infections and possibly cancer. Regulators have placed a warning on the drug label about possible increased cancer risk.

What do clinical trials show?

Clinical studies of Orencia found similar rates of cancer in patients taking the drug and those receiving a placebo. Most cancers reported were lung cancer and lymphoma, not skin cancer specifically. However, the observation period was relatively short.

How does it compare with TNF inhibitors?

TNF inhibitors such as Humira and Enbrel are known to increase skin cancer risk. The data for Orencia is less clear. One study showed patients who switched to Orencia after TNF-inhibitor exposure may have higher rates of skin cancer. It also showed higher rates among women.

When does the patent expire?

The U.S. patent for Orencia expires in 2026. Biosimilars are already under development by several companies. [1]

What side effects are patients asking about?

Patients report concern over infections, lung cancer, and skin changes. Some ask about regular skin checks by a dermatologist. Patients who have had skin cancer in the past may be advised by their doctor to avoid Orencia.

Who makes Orencia?

Orencia is made by Bristol-Myers Squibb.